Diphtheria antitoxin

Last updated
Diphtheria antitoxin
Diphtheria antitoxin 1925 (cropped).jpg
Vial of 10,000 units, circa 1925.
Clinical data
AHFS/Drugs.com Micromedex Detailed Consumer Information
Routes of
administration
IM, IV
ATC code
Identifiers
ChemSpider
  • none

Diphtheria antitoxin (DAT) is a medication made up of antibodies used in the treatment of diphtheria. [1] [2] It is no longer recommended for prevention of diphtheria. [2] [3] It is given by injection into a vein or muscle. [2]

Contents

Side effects are common. [3] They include serum sickness and allergic reactions including anaphylaxis. [2] Diphtheria antitoxin is made from the blood plasma of horses that have been immunized against diphtheria toxin. [1] It works by neutralizing the toxins produced by Corynebacterium diphtheriae . [1]

Diphtheria antitoxin was developed and came into medical use in the late 1800s. [4] The 1901 diphtheria antitoxin contamination incident, in which the milk wagon horse used to culture the antitoxin became infected with tetanus, which contaminated vials of the antitoxin leading to the deaths of several children in the midwest United States, [5] led to the passage of the Biologics Control Act of 1902 and the 1906 formation of the U.S. Food and Drug Administration (FDA). [6] [7] The celebrated 1925 serum run to Nome was a transport of the antitoxin by dog sled relay across the U.S. territory of Alaska across 674 miles (1,085 km) in 5+12 days, saving the small town of Nome and the surrounding communities from an epidemic of the disease.

Diphtheria antitoxin is on the World Health Organization's List of Essential Medicines. [8] [9] In the United States it can be obtained from the Centers for Disease Control. [1] It is not available in many countries including many in Europe as of 2008. [10]

Chemistry

One of the first bottles of Diphtheria antitoxin produced by the Hygienic Laboratory (predecessor of the NIH), c. 1895 Antitoxin diphtheria.jpg
One of the first bottles of Diphtheria antitoxin produced by the Hygienic Laboratory (predecessor of the NIH), c. 1895

It is a solution of concentrated proteins, chiefly globulins, containing antibodies obtained from the blood of horses that have been immunized against diphtheria toxin. [1]

Related Research Articles

<span class="mw-page-title-main">Diphtheria</span> Bacterial disease

Diphtheria is an infection caused by the bacterium Corynebacterium diphtheriae. Most infections are asymptomatic or have a mild clinical course, but in some outbreaks, the lethality rate approaches 10%. Signs and symptoms may vary from mild to severe, and usually start two to five days after exposure. Symptoms often develop gradually, beginning with a sore throat and fever. In severe cases, a grey or white patch develops in the throat, which can block the airway, and create a barking cough similar to what is observed in croup. The neck may also swell in part due to the enlargement of the facial lymph nodes. Diphtheria can also involve the skin, eyes, or genitals, and can cause complications, including myocarditis, inflammation of nerves, kidney problems, and bleeding problems due to low levels of platelets.

<span class="mw-page-title-main">Antivenom</span> Medical treatment for venomous bites and stings

Antivenom, also known as antivenin, venom antiserum, and antivenom immunoglobulin, is a specific treatment for envenomation. It is composed of antibodies and used to treat certain venomous bites and stings. Antivenoms are recommended only if there is significant toxicity or a high risk of toxicity. The specific antivenom needed depends on the species involved. It is given by injection.

<span class="mw-page-title-main">Antitoxin</span> Antibody with the ability to neutralize a specific toxin

An antitoxin is an antibody with the ability to neutralize a specific toxin. Antitoxins are produced by certain animals, plants, and bacteria in response to toxin exposure. Although they are most effective in neutralizing toxins, they can also kill bacteria and other microorganisms. Antitoxins are made within organisms, and can be injected into other organisms, including humans, to treat an infectious disease. This procedure involves injecting an animal with a safe amount of a particular toxin. The animal's body then makes the antitoxin needed to neutralize the toxin. Later, blood is withdrawn from the animal. When the antitoxin is obtained from the blood, it is purified and injected into a human or other animal, inducing temporary passive immunity. To prevent serum sickness, it is often best to use an antitoxin obtained from the same species.

<span class="mw-page-title-main">DPT vaccine</span> Combination vaccine

The DPT vaccine or DTP vaccine is a class of combination vaccines against three infectious diseases in humans: diphtheria, pertussis, and tetanus. The vaccine components include diphtheria and tetanus toxoids and either killed whole cells of the bacterium that causes pertussis or pertussis antigens. The term toxoid refers to vaccines which use an inactivated toxin produced by the pathogen which they are targeted against to generate an immune response. In this way, the toxoid vaccine generates an immune response which is targeted against the toxin which is produced by the pathogen and causes disease, rather than a vaccine which is targeted against the pathogen itself. The whole cells or antigens will be depicted as either "DTwP" or "DTaP", where the lower-case "w" indicates whole-cell inactivated pertussis and the lower-case "a" stands for "acellular". In comparison to alternative vaccine types, such as live attenuated vaccines, the DTP vaccine does not contain any live pathogen, but rather uses inactivated toxoid to generate an immune response; therefore, there is not a risk of use in populations that are immune compromised since there is not any known risk of causing the disease itself. As a result, the DTP vaccine is considered a safe vaccine to use in anyone and it generates a much more targeted immune response specific for the pathogen of interest.

In immunology, antiserum is a blood serum containing antibodies that is used to spread passive immunity to many diseases via blood donation (plasmapheresis). For example, convalescent serum, passive antibody transfusion from a previous human survivor, used to be the only known effective treatment for ebola infection with a high success rate of 7 out of 8 patients surviving.

<span class="mw-page-title-main">1901 diphtheria antitoxin contamination incident</span>

On October 2, 1901, a former milk wagon horse named Jim showed signs that he had contracted tetanus and was euthanized. He was used to produce serum containing diphtheria antitoxin. Jim produced over 30 US quarts of diphtheria antitoxin in his career. After the death of a girl in St. Louis, Missouri, was traced back to Jim's contaminated serum, it was discovered that serum dated September 30 contained tetanus in its incubation phase. This contamination could have easily been discovered if the serum had been tested prior to its use. Furthermore, samples from September 30 had also been used to fill bottles labeled "August 24", while actual samples from the 24th were shown to be free of contamination.

<span class="mw-page-title-main">Mumps vaccine</span> Vaccine which prevents mumps

Mumps vaccines are vaccines which prevent mumps. When given to a majority of the population they decrease complications at the population level. Effectiveness when 90% of a population is vaccinated is estimated at 85%. Two doses are required for long term prevention. The initial dose is recommended between 12 and 18 months of age. The second dose is then typically given between two years and six years of age. Usage after exposure in those not already immune may be useful.

In immunology, passive immunity is the transfer of active humoral immunity of ready-made antibodies. Passive immunity can occur naturally, when maternal antibodies are transferred to the fetus through the placenta, and it can also be induced artificially, when high levels of antibodies specific to a pathogen or toxin are transferred to non-immune persons through blood products that contain antibodies, such as in immunoglobulin therapy or antiserum therapy. Passive immunization is used when there is a high risk of infection and insufficient time for the body to develop its own immune response, or to reduce the symptoms of ongoing or immunosuppressive diseases. Passive immunization can be provided when people cannot synthesize antibodies, and when they have been exposed to a disease that they do not have immunity against.

<span class="mw-page-title-main">Hepatitis B vaccine</span> Vaccine against hepatitis B

Hepatitis B vaccine is a vaccine that prevents hepatitis B. The first dose is recommended within 24 hours of birth with either two or three more doses given after that. This includes those with poor immune function such as from HIV/AIDS and those born premature. It is also recommended that health-care workers be vaccinated. In healthy people, routine immunization results in more than 95% of people being protected.

<span class="mw-page-title-main">Hib vaccine</span> Haemophilus influenzae type B vaccine

The Haemophilus influenzae type B vaccine, also known as Hib vaccine, is a vaccine used to prevent Haemophilus influenzae type b (Hib) infection. In countries that include it as a routine vaccine, rates of severe Hib infections have decreased more than 90%. It has therefore resulted in a decrease in the rate of meningitis, pneumonia, and epiglottitis.

Procaine benzylpenicillin also known as penicillin G procaine, is an antibiotic useful for the treatment of a number of bacterial infections. Specifically it is used for syphilis, anthrax, mouth infections, pneumonia, diphtheria, cellulitis, and animal bites. It is given by injection into a muscle.

<span class="mw-page-title-main">Diphtheria vaccine</span> Vaccine against diphtheria

Diphtheria vaccine is a toxoid vaccine against diphtheria, an illness caused by Corynebacterium diphtheriae. Its use has resulted in a more than 90% decrease in number of cases globally between 1980 and 2000. The first dose is recommended at six weeks of age with two additional doses four weeks apart, after which it is about 95% effective during childhood. Three further doses are recommended during childhood. It is unclear if further doses later in life are needed.

<span class="mw-page-title-main">Cholera vaccine</span> Vaccine to prevent cholera

A cholera vaccine is a vaccine that is effective at preventing cholera. For the first six months after vaccination it provides about 85 percent protection, which decreases to 50 percent or 62 percent during the first year. After two years the level of protection decreases to less than 50 percent. When enough of the population is immunized, it may protect those who have not been immunized.

Meningococcal vaccine refers to any vaccine used to prevent infection by Neisseria meningitidis. Different versions are effective against some or all of the following types of meningococcus: A, B, C, W-135, and Y. The vaccines are between 85 and 100% effective for at least two years. They result in a decrease in meningitis and sepsis among populations where they are widely used. They are given either by injection into a muscle or just under the skin.

<span class="mw-page-title-main">Tick-borne encephalitis vaccine</span> Vaccine against tick-borne encephalitis

Tick-borne encephalitis vaccine is a vaccine used to prevent tick-borne encephalitis (TBE). The disease is most common in Central and Eastern Europe, and Northern Asia. More than 87% of people who receive the vaccine develop immunity. It is not useful following the bite of an infected tick. It is given by injection into a muscle.

Snake antivenom is a medication made up of antibodies used to treat snake bites by venomous snakes. It is a type of antivenom.

<span class="mw-page-title-main">Tetanus vaccine</span> Vaccines used to prevent tetanus

Tetanus vaccine, also known as tetanus toxoid (TT), is a toxoid vaccine used to prevent tetanus. During childhood, five doses are recommended, with a sixth given during adolescence.

The Botulism Antitoxin Heptavalent - (Equine) – BAT, made by Emergent BioSolutions Canada Inc. – is a licensed, commercially available botulism anti-toxin that effectively neutralizes all seven known botulinum nerve toxin serotypes. It is indicated for sporadic cases of life-threatening botulism and is also stockpiled for the eventuality of botulinum nerve toxins being used in a future bioterrorist attack.

Rabies immunoglobulin (RIG) is a medication made up of antibodies against the rabies virus. It is used to prevent rabies following exposure. It is given after the wound is cleaned with soap and water or povidone-iodine and is followed by a course of rabies vaccine. It is given by injection into the site of the wound and into a muscle. It is not needed in people who have been previously vaccinated against rabies.

<span class="mw-page-title-main">Anti-tetanus immunoglobulin</span> Medication made up of antibodies against the tetanus toxin

Anti-tetanus immunoglobulin, also known as tetanus immune globulin (TIG) and tetanus antitoxin, is a medication made up of antibodies against the tetanus toxin. It is used to prevent tetanus in those who have a wound that is at high risk, have not been fully vaccinated with tetanus toxoid, or have HIV/AIDS. It is used to treat tetanus along with antibiotics and muscle relaxants. It is given by injection into a muscle. Part of the dose is injected at the site of the wound.

References

  1. 1 2 3 4 5 "Our Formulary | Infectious Diseases Laboratories | CDC". www.cdc.gov. 22 September 2016. Archived from the original on 16 December 2016. Retrieved 9 December 2016.
  2. 1 2 3 4 World Health Organization (2009). Stuart MC, Kouimtzi M, Hill SR (eds.). WHO Model Formulary 2008. World Health Organization. p. 397. hdl:10665/44053. ISBN   9789241547659.
  3. 1 2 British national formulary : BNF 69 (69 ed.). British Medical Association. 2015. p. 850. ISBN   9780857111562.
  4. Hau J, Schapiro SJ, Van Hoosier Jr GL (2004). Handbook of Laboratory Animal Science (Second: Animal Models ed.). CRC Press. p. 6. ISBN   9781420039627. Archived from the original on 2017-09-23.
  5. "The St. Louis Tragedy and Enactment of the 1902 Biologics Control Act". U.S. Food and Drug Administration. April 9, 2009. Archived from the original on February 18, 2014.
  6. "100 Years of Biologics Regulation" (PDF). U.S. Food and Drug Administration. April 21, 2009.
  7. "Science and the Regulation of Biological Products". U.S. Food and Drug Administration. April 9, 2009.
  8. World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl: 10665/325771 . WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  9. World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl: 10665/345533 . WHO/MHP/HPS/EML/2021.02.
  10. Wagner KS, Stickings P, White JM, Neal S, Crowcroft NS, Sesardic D, Efstratiou A (December 2009). "A review of the international issues surrounding the availability and demand for diphtheria antitoxin for therapeutic use". Vaccine. 28 (1): 14–20. doi:10.1016/j.vaccine.2009.09.094. PMID   19818425.